AB088. FTY720 supplementation partially improves erectile dysfunction in rats with streptozotocin-induced type 1 diabetes through inhibition of endothelial dysfunction and corporal fibrosis
Printed Abstracts

AB088. FTY720 supplementation partially improves erectile dysfunction in rats with streptozotocin-induced type 1 diabetes through inhibition of endothelial dysfunction and corporal fibrosis

Kai Cui, Yajun Ruan, Zhe Tang, Ke Rao, Tao Wang, Shaogang Wang, Zhong Chen, Jihong Liu

Department of Urology, Tongji medical College, Huazhong University of Science & Technology, Wuhan 430030, China


Background: To investigate whether FTY720, approved in 2010 for the treatment of patients with the relapsing-remitting form of multiple sclerosis, could ameliorate erectile dysfunction induced by diabetes mellitus (DMED).

Methods: Thirty-two Sprague-Dawley rats (8 weeks old) were induced type I DM and the other eight rats formed the control (n=8). Eight weeks later, 17 rats with DMED tested with an apomorphine test were divided in two groups: DMED (n=8) and DMED + FTY720 (1 mg/kg/d; n=9). Treatment of FTY720 lasted for 4 weeks.

Results: Impaired erectile function, inhibited S1P3/Akt/NO/cGMP activity, serious corporal fibrosis and over-activated pathways (the Smad and non-Smad) were found in the DMED group compared with the control, while FTY720 partly but significantly improved these pathological changes induced by DM.

Conclusions: FTY720 supplementation inhibited endothelial dysfunction and corporal fibrosis, ultimately leading to partial improvement of DMED in rats. This finding provides evidence for a potential treatment method for DMED.

Keywords: Erectile dysfunction; diabetes mellitus; endothelial function; corporal fibrosis


doi: 10.21037/tau.2017.s088


Cite this abstract as: Cui K, Ruan Y, Tang Z, Rao K, Wang T, Wang S, Chen Z, Liu J. FTY720 supplementation partially improves erectile dysfunction in rats with streptozotocin-induced type 1 diabetes through inhibition of endothelial dysfunction and corporal fibrosis. Transl Androl Urol 2017;6(Suppl 3):AB088. doi: 10.21037/tau.2017.s088